Supernus Pharmaceuticals, Inc.
SUPN
Helyezés a részvények között
#5893
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
Részvényárfolyam
$37.86
Utolsó szinkronizálás: 2026-10-16
Piaci kapitalizáció
$2.20B
Változás (1 nap)
-4.32%
Változás (1 év)
-23.08%
Ország
US
Kereskedés Supernus Pharmaceuticals, Inc. (SUPN)
Kategória
Healthcare
Piaci kapitalizációja Supernus Pharmaceuticals, Inc.(SUPN)
Piaci kapitalizáció: $2.20B
October 2026-ban a Supernus Pharmaceuticals, Inc. piaci kapitalizációja $2.20B. Ez alapján a Supernus Pharmaceuticals, Inc. a világ 5893rd legértékesebb vállalata a piaci kapitalizáció szerint. A piaci kapitalizáció egy tőzsdén jegyzett vállalat összes részvényének piaci értéke, amelyet gyakran használnak a vállalat értékének mérésére.
Supernus Pharmaceuticals, Inc. piaci kapitalizációjának története 2018 és 2026 között
SUPN összehasonlítva az 5 legnépszerűbb stocks
